Ragweed Pollen Allergy Treatment Market was valued at US$836.9 million in 2020 Key Players Anergis SA, Biomay AG and Astellas Pharma Inc., Thermo Fisher Scientific Inc.

A New Market Study on the Ragweed Pollen Allergy Treatment Market 2022-2028 with 100+ Market Data Tables, Circle Chat and Page-Spread Graphs and Figures and Easy to Read Detailed Analysis to understand. Currently, the market is expanding its presence. The research report presents a comprehensive assessment of the market and contains future trend, current growth factors, careful opinions, facts and industry-validated market data. The report incorporates broad evaluation of different methods such as combinations and acquisitions, advancements, investigations, and improvements adopted by observable market pioneers to stay ahead in the overall market.

Get a PDF brochure with the latest insights @ https://www.coherentmarketinsights.com/insight/request-pdf/4054

The increasing prevalence of ragweed pollen allergy is driving the growth of the global ragweed pollen allergy treatment market. According to the American College of Allergy, Asthma, and Immunology, 2020, there are about 17 species of ragweed in the United States. Weeds grow in most parts of the United States, usually flowering and producing fine powdered pollen from August through November. Ragweed-associated allergies are treated with antihistamines and other allergy-related medications.

Additionally, changes in climatic conditions and increasing pollution are other major factors driving the growth of the global ragweed pollen allergy treatment market. For example, according to the Asthma and Allergy Foundation of America (AAFA), approximately 23 million people in the United States have symptoms of ragweed pollen allergy by the end of summer. These symptoms can depress the lives of allergy sufferers, which can also cause asthma symptoms in allergic asthmatics.

Global Ragweed Pollen Allergy Treatment Market – Impact Analysis of COVID-19

The growth of the global ragweed pollen allergy treatment market is affected to some extent by the COVID-19 outbreak as it is difficult to conduct clinical trials during the pandemic. However, the overall market is witnessing optimistic growth owing to the similarity of symptoms of COVID-19 and ragweed pollen allergy.

The global version of the report will include the impact of COVID-19 and the probable changes in the future outlook of the industry, considering the technological, social, political and economic parameters.

The global ragweed allergy treatment market is estimated at USD 836.9 million in 2020 and is expected to register a CAGR of 4.61% during the forecast period (2020-2027).

Rising number of clinical trials of therapies for the treatment of ragweed pollen allergy and strategic collaborations are expected to augment the market growth over the forecast period

The key players are heavily involved in the research and development of advanced drugs and new therapies. This is expected to drive the growth of the market over the forecast period

For example, in May 2015, two Austrian-based biotechnology companies, Biomay and VTU Technology, entered into a collaboration licensing agreement to produce recombinant allergens. Biomay had previously succeeded in producing and delivering a major allergen from ragweed pollen as a recombinant product. Under the terms of the agreement, VTU Technology will receive royalties based on the worldwide sale of recombinant allergens produced by Biomay.

For example, in September 2018, Genentech’s Xolair received US FDA approval for the treatment of allergies. Xolair is the only biological product approved for allergic asthma as well as chronic idiopathic urticaria. The product is already approved to treat patients 12 years and older with allergic asthma. According to Genentech, this approval will help address the unmet needs of patients and caregivers or parents.

Buy this report and get early access (fixed USD 2000 OFF) – https://www.coherentmarketinsights.com/promo/buynow/4054

Global Ragweed Pollen Allergy Treatment Market – Constraints

Lack of awareness regarding allergy immunotherapy is expected to hamper the growth of the global ragweed pollen allergy treatment market. Additionally, side effects associated with Allergy Immunotherapy are another key factor expected to limit the market growth.

Additionally, the high costs associated with the treatment of ragweed pollen allergy are expected to hamper the market growth over the forecast period.

Cover of Ragweed Pollen Allergy Treatment Market Report

Report cover Details
Year of reference : 2019 Market size in 2019: US$836.9 million
Historical data for: 2016 to 2019 Forecast period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 4.6% 2027 value projection: US$1,147.3 million
Geographical areas covered:
  • North America: United States and Canada
  • Latin America: Brazil, Argentina, Mexico and Rest of Latin America
  • Europe: Germany, UK, Spain, France, Italy, Russia and rest of Europe
  • Asia-Pacific: China, India, Japan, Australia, South Korea, ASEAN and Rest of Asia-Pacific
  • Middle East: GCC, Israel, Rest of Middle East
  • Africa: South Africa, North Africa and Central Africa
Segments covered:
  • By drug class: antihistamines, decongestants, nasal corticosteroids, others.
  • By distribution channel: hospital pharmacy, retail pharmacy, online channel.
Companies covered: ALK-Abello A/S, ASIT Biotech SA, Anergis SA, Biomay AG, Astellas Pharma Inc., Thermo Fisher Scientific Inc, Siemens Healthcare Private Limited, Omega Diagnostics Group PLC, Stallergenes Greer, bioMérieux SA, Lincoln Diagnostics, Inc, HOB Biotech Group Corp Ltd, HYCOR Biomedical, Inc, Alcon, Hitachi Chemical Diagnostics, Inc, Quest Diagnostics Incorporated, Circassia, Immunomic Therapeutics, Inc, Novartis AG, Japan Tobacco Inc, GlaxoSmithKline plc, REGiMMUNE Co, Ltd, Sanofi and Merck KGaA.
Growth drivers:
  • Increasing environmental pollution and changing lifestyle
  • The growing demand for advanced therapies for the treatment of ragweed pollen allergy
Constraints and challenges:
  • High costs of treating ragweed pollen allergy
  • Lack of awareness regarding allergic immunotherapy among patients

Global Ragweed Pollen Allergy Treatment Market – Regional Analysis

The North American market accounted for the largest share of the global market ragweed pollen allergy treatment in 2019 as it is one of the most common causes of allergies in the region. Moreover, the major players are strongly focusing on obtaining product approvals and clinical trials of drugs for the treatment of ragweed pollen allergy, which is expected to propel the growth of the market. For example, the United States Food and Drug Administration (FDA) recently approved two new prescription drugs, Ragwitek and Grastek, for the treatment of ragweed pollen and grass pollen allergy.

For example, in April 2020, ALK, a Danish research-based pharmaceutical company, announced Health Canada’s approval of ITULATEK SLIT tablets for the treatment of tree pollen allergy. ITULATEKTM is available in Canada and is ALK’s fourth once-daily SLIT (sublingual allergy immunotherapy) tablet. This tablet is indicated in allergic immunotherapy for the moderate treatment of allergic rhinitis induced by alder, birch or hazel pollen in adults aged 18 to 65 with a clinical history of allergic rhinitis.

Furthermore, the European market is also expected to witness significant growth thanks to the initiatives taken by key players and for the treatment of ragweed pollen allergy. For example, in February 2017, ALK submitted a registration application for “Ragweed SLIT-tablet” in Europe. The tablet was accepted for examination via a decentralized procedure by the competent health authorities, with Germany being the reference Member State. The indication proposed by the company is the treatment of patients between the ages of 18 and 65 with ragweed allergic conjunctivitis and/or rhinitis, despite the use of symptomatic relief medication.

Global Ragweed Pollen Allergy Treatment Market – Competitive Landscape

The key players operating in the global ragweed pollen allergy treatment market are ALK-Abello A/S, ASIT Biotech SA, Anergis SA, Biomay AG and Astellas Pharma Inc., Thermo Fisher Scientific Inc, Siemens Healthcare Private Limited, Omega Diagnostics Group PLC, Stallergenes Greer, bioMérieux SA, Lincoln Diagnostics, Inc, HOB Biotech Group Corp Ltd, HYCOR Biomedical, Inc, Alcon, Hitachi Chemical Diagnostics, Inc, Quest Diagnostics Incorporated, Circassia, Immunomic Therapeutics, Inc, Novartis AG, Japan Tobacco Inc, GlaxoSmithKline plc, REGiMMUNE Co, Ltd, Sanofi and Merck KGaA.

Get sample report with latest Covid19 impact analysis @ https://www.coherentmarketinsights.com/insight/request-sample/4054

Contents

Chapter 1 Introduction

1.1. Description of the report

1.1.1. Purpose of the report

1.1.2. USPs and key offers

1.2. Main benefits for stakeholders

1.3. Target audience

1.4. Report scope

Chapter No. 2 Executive Summary

2.1. Main conclusions

2.1.1. Best Investment Pockets

2.1.1.1. Market Attractiveness Analysis, By Type

2.1.1.2. Market attractiveness analysis, by end use

2.1.1.3. Market attractiveness analysis, by region

2.2. Market overview

2.3. Global Ragweed Pollen Allergy Treatment Market, 2017-2022 (USD Million)

2.4. Views of key informants

Chapter No. 3 Impact Analysis of COVID 19

3.1. Assessment of the impact of the COVID-19 pandemic, by region

3.1.1. North America

3.1.2. Europe

3.1.3. Asia Pacific

3.1.4. Latin America

3.1.5. The Middle East and Africa

About Us:

Coherent Market Insights is a global market intelligence and advisory organization that provides syndicated research reports, custom research reports and advisory services. We’re known for our actionable insights and genuine reports in a variety of fields, including aerospace and defense, agriculture, food and beverage, automotive, chemicals and materials, and virtually any field and an exhaustive list of subdomains under the sun. We create value for our clients through our highly reliable and accurate reports. We are also committed to playing a leadership role in providing insights in various post-COVID-19 sectors and to continuing to deliver measurable and sustainable results to our clients.

Contact:

Consistent market information
1001 4th Ave, #3200 Seattle, WA 98154, USA
Email: [email protected]
United States of America: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Comments are closed.